Abstract: A system, and its associated methodology, for detecting cTnl includes a patient sample such as whole blood, serum or plasma, anti-cTnl antibodies conjugated with ligand-capped metallic nanoparticles, and a spectrophotometer operable to detect a shift of wavelength in light resulting from binding of cTnl to the anti-cTnl antibodies conjugated with ligand-capped metallic nanoparticles. By measuring changes in Localized Surface Plasmon Resonance of the anti-cTnl antibodies conjugated with ligand-capped metallic nanoparticles the presence of cTnl can be detected.